VBI Vaccines Announced Interim Data From The Phase 1 Study Of Its Multivalent Pan-coronavirus Vaccine Candidate, VBI-2901, Based On Interim Data, Peak Responses Were Achieved With Only A Single 10µg Dose Of VBI-2901
Portfolio Pulse from Benzinga Newsdesk
VBI Vaccines has announced interim data from the Phase 1 study of its multivalent pan-coronavirus vaccine candidate, VBI-2901. The data suggests that peak responses were achieved with only a single 10µg dose of VBI-2901.
September 27, 2023 | 11:34 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
VBI Vaccines' Phase 1 study data shows promising results for its pan-coronavirus vaccine candidate, VBI-2901. This could potentially boost the company's stock in the short term.
The announcement of positive interim data from a Phase 1 study is typically a positive catalyst for biotech companies. This news suggests that VBI Vaccines' VBI-2901 vaccine candidate is showing promising results, which could potentially lead to increased investor interest and a rise in the company's stock price in the short term.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 100